PMID- 33966583
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20210624
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 6
DP  - 2021 Jun
TI  - Real-world evidence on survival, adverse events, and health care burden in 
      Medicare patients with mantle cell lymphoma.
PG  - 1325-1334
LID - 10.1080/10428194.2021.1919662 [doi]
AB  - Most data on overall survival (OS) and adverse events (AEs) in patients with 
      mantle cell lymphoma (MCL) are from controlled trials; therefore, in this 
      population-based study, we retrospectively assessed treatment patterns, OS, and 
      AEs in MCL patients initiating systemic treatment during 2013-2015 using the 
      United States Medicare claims database. Among 1390 eligible patients (median age 
      = 74 years), chemoimmunotherapy with bendamustine/rituximab (BR) was the 
      preferred choice in first-line (35.3%), followed by ibrutinib (33.5%), rituximab 
      (9.1%), and rituximab/cyclophosphamide/doxorubicin/vincristine (R-CHOP) (6.8%). 
      Twenty-four-month OS was 73% for BR; 47%, ibrutinib; 72%, rituximab; and 71%, 
      R-CHOP. For the four most commonly used regimens, neutropenia, anemia, 
      hypertension, and infection were the most frequent AEs. Patients with >/=3 AEs had 
      nearly four times higher monthly costs than those with 0-2 AEs in the first 
      observed therapy line. Findings demonstrate a substantial increase in the 
      economic burden as the number of AEs increased among the Medicare MCL patients.
FAU - Goyal, Ravi K
AU  - Goyal RK
AUID- ORCID: 0000-0003-1632-036X
AD  - Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, 
      USA.
FAU - Jain, Preetesh
AU  - Jain P
AD  - Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
FAU - Nagar, Saurabh P
AU  - Nagar SP
AD  - Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, 
      USA.
FAU - Le, Hannah
AU  - Le H
AD  - US HEOR Oncology, AstraZeneca, Gaithersburg, MD, USA.
FAU - Kabadi, Shaum M
AU  - Kabadi SM
AD  - Epidemiology and Real-World Evidence in Oncology, AstraZeneca, Gaithersburg, MD, 
      USA.
FAU - Davis, Keith
AU  - Davis K
AD  - Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, 
      USA.
FAU - Kaye, James A
AU  - Kaye JA
AD  - Department of Epidemiology, RTI Health Solutions, Waltham, MA, USA.
FAU - Du, Xianglin L
AU  - Du XL
AD  - The University of Texas Health Science Center at Houston, Houston, TX, USA.
FAU - Wang, Michael
AU  - Wang M
AUID- ORCID: 0000-0001-9748-5486
AD  - Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210508
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Bendamustine Hydrochloride/therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Delivery of Health Care
MH  - Doxorubicin/therapeutic use
MH  - Humans
MH  - *Lymphoma, Mantle-Cell/drug therapy
MH  - Medicare
MH  - Prednisone/therapeutic use
MH  - Retrospective Studies
MH  - Rituximab/adverse effects
MH  - United States/epidemiology
MH  - Vincristine/therapeutic use
OTO - NOTNLM
OT  - MCL
OT  - Mantle cell lymphoma
OT  - adverse events
OT  - costs
OT  - economic burden
OT  - treatment patterns
EDAT- 2021/05/11 06:00
MHDA- 2021/06/25 06:00
CRDT- 2021/05/10 05:36
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2021/05/10 05:36 [entrez]
AID - 10.1080/10428194.2021.1919662 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Jun;62(6):1325-1334. doi: 10.1080/10428194.2021.1919662. Epub 
      2021 May 8.